Company profile: Aura Biosciences
1.1 - Company Overview
Company description
- Provider of virus-like drug conjugates (VDCs) using virus-like particles to target solid tumors by delivering cytotoxic drugs or nucleic acids. Develops Belzupacap Sarotalocan (Bel-sar) for first-line treatment of early-stage choroidal melanoma and other ocular oncology indications, with potential in choroidal metastasis, aiming to preserve vision and prevent metastatic disease.
Products and services
- Virus-Like Drug Conjugates (VDCs): A VLP-based platform that uses virus-like particles to target solid tumors by delivering cytotoxic drugs or nucleic acids, promoting cancer cell death via a dual mechanism
- Belzupacap Sarotalocan (Bel-sar): An in-development virus-like drug conjugate engineered for first-line early-stage choroidal melanoma and other ocular oncology indications, aiming to preserve vision and prevent metastatic disease
- Choroidal Melanoma Treatment: A first-line therapeutic approach utilizing Bel-sar for early-stage choroidal melanoma to preserve vision and prevent metastatic disease in ocular oncology patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aura Biosciences
Omega Therapeutics
HQ: United States
Website
- Description: Provider of a proprietary epigenomic programming platform (OMEGA Platform) to develop therapeutics by controlling gene expression; conducts the MYCHELANGELO Phase 1/2 trial in non-small cell lung cancer; runs IND-enabling preclinical studies in inflammation/immunology and other diseases to assess gene targets; and offers an expanded access policy for investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omega Therapeutics company profile →
C3J Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage bacteriophage therapeutics and a synthetic phage platform to engineer phages for multidrug-resistant infections, including AP-PA02 for Pseudomonas aeruginosa respiratory disease in cystic fibrosis and non-CF bronchiectasis, AP-PA03 for acute pneumonia (hospital-acquired and ventilator-associated), and AP-SA02 for Staphylococcus aureus bacteremia and potential prosthetic joint infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C3J Therapeutics company profile →
AccuraGen
HQ: United States
Website
- Description: Provider of cancer early detection solutions: a liquid biopsy platform using unique biochemistry and machine learning to extract cancer signals in plasma for treatment guidance, minimal residue disease detection, and early screening; and CLAmp-seq technology to detect multiple cancer signals in blood and analyze them with machine learning for multi-cancer early detection tests.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AccuraGen company profile →
Modis Therapeutics
HQ: United States
Website
- Description: Provider of disease-modifying therapies to patients with rare genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Modis Therapeutics company profile →
Protypia
HQ: United States
Website
- Description: Provider of high-quality, targeted tissue-based protein and peptide mass spectrometry. Offers a Targeted Proteomics Platform that quantifies drug target systems in various biological samples, integrating protein-level pharmacology and pathology across therapeutic areas, and MS Protein Analysis to identify therapeutic targets and protein features related to drug resistance and response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protypia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aura Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aura Biosciences
2.2 - Growth funds investing in similar companies to Aura Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aura Biosciences
4.2 - Public trading comparable groups for Aura Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →